EUVIMEDEUVIMED entdecken
Crossref

Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer

Wenjuan Ma, Yuting Yang, Zhiqiang Liu, Rui Zhao, Qianyi Wan, Xingyu Chen, Bicai Tang, Yong Zhou iD, Yunfeng Lin iD

ACS Applied Materials & Interfaces · 2023

DOI: 10.1021/acsami.3c07344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2023. Verfasst von Wenjuan Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of S…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Aptamers, Nucleotide, Nucleic Acids, Immunoconjugates. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, National Key Research and Development Program of China, Sichuan Province Youth Science and Technology Innovation Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody drug conjugates (ADCs) have shown promise to be the mainstream chemotherapeutics for advanced HER2-positive cancers, yet the issues of poor drug delivery efficiency, limited chemotherapeutic effects, severe immune responses, and drug resistance remain to be addressed before the clinical applications of ADCs. The DNA aptamer-guided drug conjugates (ApDCs) are receiving growing attention for specific tumors due to their excellent tumor affinity and low cost. Therefore, developing a multivalent ApDC nanomedicine by combining anti-HER2 aptamer (HApt), tetrahedral framework nucleic acid (tFNA), and deruxtecan (Dxd) together to form HApt-tFNA@Dxd might help to address these concerns. In this study, the HER2-targeted DNA aptamer modified DNA tetrahedron (HApt-tFNA) was employed as a system for drug delivery, and the adoption of tFNA could effectively enlarge the drug-loading rate compared to aptamer-guided ApDCs previously reported. Compared with free Dxd and tFNA@Dxd, HApt-tFNA@Dxd showed better structural stability, excellent targeted cytotoxicity to HER2-positive gastric cancer, and increased tissue aggregation ability in tumors. These features and superiorities make HApt-tFNA@Dxd a promising chemotherapeutic medicine for HER2-positive tumors. Our work developed a new targeting nanomedicine by combining DNA nanomaterials and chemotherapeutic agents, which represents a critical advance toward developing novel DNA-based nanomaterials and promoting their potential applications for HER2-positive cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAptamers, NucleotideNucleic AcidsImmunoconjugatesHumansPharmaceutical PreparationsDrug Delivery Systems

Stichwörter der Autor:innen

DNA tetrahedronHER2-positive gastric canceranti-HER2 aptameraptamer drug conjugatesderuxtecan

Substanzen

Pharmaceutical PreparationsAptamers, NucleotideNucleic AcidsImmunoconjugates

Autor:innen und Institutionen

  • State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P. R. China.
  • Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China.
  • Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P. R. China.
  • Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.

ORCID-Profile: Yong Zhou, Yunfeng Lin

Förderung

  • West China Hospital, Sichuan University
  • National Key Research and Development Program of China
  • Sichuan Province Youth Science and Technology Innovation Team
  • National Natural Science Foundation of China
  • Sichuan Province Science and Technology Support Program
  • West China Hospital of Stomatology, Sichuan University

Zitieren

APA

Ma, W., Yang, Y., Liu, Z., Zhao, R., Wan, Q., Chen, X., Tang, B., Zhou, Y., & Lin, Y. (2023). Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c07344

Vancouver

Ma W, Yang Y, Liu Z, Zhao R, Wan Q, Chen X, et al. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c07344

BibTeX
@article{Ma2023,
  author = {Ma, Wenjuan and Yang, Yuting and Liu, Zhiqiang and Zhao, Rui and Wan, Qianyi and Chen, Xingyu and Tang, Bicai and Zhou, Yong and Lin, Yunfeng},
  title = {Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2023},
  doi = {10.1021/acsami.3c07344}
}
Kostenlos starten →